Integrative oncology for young adults with cancer: A prospective pragmatic controlled trial
Medical Oncology · 23.06.2026 · 43 (7)
DOI: 10.1007/s12032-026-03312-8 ↗Kurz gefasst
Pragmatische Studie in der Zeitschrift Medical Oncology, online erschienen am 23.06.2026. Verfasst von Eran Ben-Arye und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. eranben@technion.ac.il. Hauptthemen laut MEDLINE: Neoplasms, Quality of Life, Integrative Oncology. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technion - Israel Institute of Technology.
Abstract (Originalsprache)
Research on the impact of integrative oncology (IO) programs on quality of life (QoL) among young adults with cancer is limited. The present study explored the impact of a patient-tailored IO program for young patients undergoing active oncology care. This pragmatic, prospective and preference-controlled study examined patients aged 18–45 referred by oncology healthcare providers to an IO consultation and 6 weekly treatments addressing QoL-related concerns. High adherence to integrative care (high-AIC, vs. low-AIC) was defined as attending ≥ 4 IO sessions, with baseline and 6-week symptoms assessed using ESAS (Edmonton Symptom Assessment Scale); EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) and MYCAW (Measure Yourself Concerns and Wellbeing) tools. Of 180 patients, 137 (76%) were high-AIC, with similar baseline demographic, cancer-and QoL-related characteristics in both groups. At 6 weeks, high-AIC patients reported greater improvement on ESAS ( p = 0.046) and MYCAW ( p = 0.008) wellbeing; ESAS nausea ( p = 0.027); EORTC dyspnea; and EORTC role functioning ( p = 0.031). Significant within-group improvement was observed in older high-AIC patients (aged 40–45, n = 72), as opposed to no improvement in young high-AIC patients (aged 18–39, n = 65) on ESAS fatigue ( p = 0.033), anxiety ( p = 0.001), and breathing ( p = 0.016); and wellbeing on ESAS ( p = 0.006) and MYCAW ( p < 0.001). Young patients with cancer highly adherent to a 6-week IO program reported significantly improved wellbeing, more significantly among older patients. Further research is needed to explore the impact of IO programs on young patients with cancer, addressing their unique psychological, social, and spiritual needs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. eranben@technion.ac.il.
- Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, Haifa, Israel. eranben@technion.ac.il.
- The Oncology Service, Lin Medical Center, 35 Rothschild St, Haifa, Israel. eranben@technion.ac.il.
- Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
- Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, Haifa, Israel.
- The Oncology Service, Lin and Zebulun Medical Centers, Clalit Health Services, Haifa, Israel.
Förderung
- Technion - Israel Institute of Technology
Zitieren
APA
Ben-Arye, E., Samuel, S., Turgeman, I., Samuels, N., Stein, N., & Gressel, O. (2026). Integrative oncology for young adults with cancer: A prospective pragmatic controlled trial. Medical Oncology, 43(7). https://doi.org/10.1007/s12032-026-03312-8
Vancouver
Ben-Arye E, Samuel S, Turgeman I, Samuels N, Stein N, Gressel O. Integrative oncology for young adults with cancer: A prospective pragmatic controlled trial. Medical Oncology. 2026;43(7). doi:10.1007/s12032-026-03312-8
BibTeX
@article{BenArye2026,
author = {Ben-Arye, Eran and Samuel, Shahar and Turgeman, Ilit and Samuels, Noah and Stein, Nili and Gressel, Orit},
title = {Integrative oncology for young adults with cancer: A prospective pragmatic controlled trial},
journal = {Medical Oncology},
year = {2026},
volume = {43},
number = {7},
doi = {10.1007/s12032-026-03312-8}
}
EUVIMED